Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Saved in:
| Title: | Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. |
|---|---|
| Authors: | Tiedt R; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., King FJ; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Stamm C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Niederst MJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA. Electronic address: matt.niederst@novartis.com., Delach S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Zumstein-Mecker S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Meltzer J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Mulford IJ; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Labrot E; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Engstler BS; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Baltschukat S; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Kerr G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Golji J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Wyss D; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Schnell C; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland., Ainscow E; Novartis Institutes for BioMedical Research, Genomics Institute of the Novartis Research Foundation, La Jolla, CA, USA., Engelman JA; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Sellers WR; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Barretina J; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Caponigro G; Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA., Porta DG; Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland. |
| Source: | Cell reports [Cell Rep] 2023 Apr 25; Vol. 42 (4), pp. 112297. Date of Electronic Publication: 2023 Mar 23. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
